INDIANAPOLIS (TheStreet) -- Eli Lilly (LLY) will lay off some 5,500 employees by the end of 2011, as the drugmaker prepares to face a slew of patent expirations, including one on its best-selling drug, the antipsychotic Zyprexa.
The Indianapolis company also said it would reorganize itself into four business units and strive to cut costs by $1 billion a year, also by the end 2011.
Or, as Lilly called the moves in its press release announcing the layoffs and the restructuring: "Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients."
The job cuts will bring the company's work force to 35,500 from 40,500. But Lilly also said it expects to hire people in emerging markets and in Japan, where business is growing fastest.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV